The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Cefodizme     (6R,7S)-7-[[(2Z)-2-(2-amino- 1,3-thiazol-4...

Synonyms: Diezime, Modivid, Timecef, Cefodizima, Cefodizime, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Cefodizime

 

High impact information on Cefodizime

  • One day after surgery E. coli- and S. aureus-driven neutrophil ROI production was not different from the preoperative values (-2 and +12%, respectively, for the cefodizime group and +7 and +15%, respectively, for the cefuroxime group; P > 0.15 for all) [5].
  • In both groups the mean phagocytic ability for E. coli and S. aureus decreased during surgery (-21 and -8%, respectively, for the cefodizime group and -39 and -38%, respectively, for the cefuroxime group; P < 0.05 for all) [5].
  • The effects of cefodizime and cefuroxime on neutrophil phagocytosis and reactive oxygen production in 54 patients undergoing elective coronary artery bypass grafting were studied [5].
  • The study was carried out to determine the concentrations of cefodizime (single 2-g intravenous [i.v.] dose) and ceftriaxone (single 2-g i.v. dose) in the sera and bones of 42 patients (18 women and 24 men) undergoing hip arthroplasty [6].
  • Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers [7].
 

Chemical compound and disease context of Cefodizime

 

Biological context of Cefodizime

  • Cefodizime was very stable to hydrolysis by Richmond-Sykes type I, II, III, and IV beta-lactamases, as well as the enzyme derived from Bacillus cereus [13].
  • Cefodizime was not hydrolyzed by common plasmid or chromosomal beta-lactamases, and it inhibited type I beta-lactamases [14].
  • Determinations of the extractable activities of DNA-synthesizing enzymes from cefodizime-treated Molt-4 cells showed a direct correlation between cell growth and DNA polymerase alpha as well as terminal deoxynucleotidyl transferase activity; the DNA polymerase beta activity remained unchanged [9].
  • Furthermore, increased non-opsonin dependent stimulation of the PMN oxidative burst was obtained; the strongest response was observed with cefodizime-treated P. aeruginosa in the case of low responder PMN, which displayed a deficient response after stimulation by control bacteria [10].
  • Conversely, cefodizime at 100 mg/l had no enhancing effect on diabetic neutrophil chemotaxis, but decreased the chemotactic activity of healthy neutrophils (1.1 +/- 0.2 vs 3.6 +/- 0.7, P less than 0.01) [15].
 

Anatomical context of Cefodizime

 

Associations of Cefodizime with other chemical compounds

 

Gene context of Cefodizime

 

Analytical, diagnostic and therapeutic context of Cefodizime

References

  1. Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Korting, H.C., Schäfer-Korting, M., Maass, L., Klesel, N., Mutschler, E. Antimicrob. Agents Chemother. (1987) [Pubmed]
  2. Atomic force microscopy: application to investigation of Escherichia coli morphology before and after exposure to cefodizime. Braga, P.C., Ricci, D. Antimicrob. Agents Chemother. (1998) [Pubmed]
  3. Influence of cefodizime on pulmonary inflammatory response to heat-killed Klebsiella pneumoniae in mice. Bergeron, Y., Deslauriers, A.M., Ouellet, N., Gauthier, M.C., Bergeron, M.G. Antimicrob. Agents Chemother. (1999) [Pubmed]
  4. In vitro activity of cefodizime (HR-221). Ahonkhai, V.I., Cherubin, C.E., Shulman, M.A. Antimicrob. Agents Chemother. (1982) [Pubmed]
  5. Prospective randomized comparison of cefodizime versus cefuroxime for perioperative prophylaxis in patients undergoing coronary artery bypass grafting. Wenisch, C., Bartunek, A., Zedtwitz-Liebenstein, K., Hiesmayr, M., Parschalk, B., Pernerstorfer, T., Graninger, W. Antimicrob. Agents Chemother. (1997) [Pubmed]
  6. Pharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplasty. Scaglione, F., De Martini, G., Peretto, L., Ghezzi, R., Baratelli, M., Arcidiacono, M.M., Fraschini, F. Antimicrob. Agents Chemother. (1997) [Pubmed]
  7. Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers. Lenfant, B., Namour, F., Logeais, C., Coussediere, D., Rivault, O., Bryskier, A., Surjus, A. Antimicrob. Agents Chemother. (1995) [Pubmed]
  8. Randomized comparative study of 0.5 and 1 g of cefodizime (HR 221) versus 1 g of cefotaxime for acute uncomplicated urogenital gonorrhea. van der Willigen, A.H., Wagenvoort, J.H., Schalla, W.O., Knapp, J.S., Boot, J.M., Heeres-Weststrate, P.L., Michel, M.F., van Klingeren, B., Stolz, E. Antimicrob. Agents Chemother. (1988) [Pubmed]
  9. Differential stimulation of lymphocyte cell growth in vitro by cephalosporins. Leyhausen, G., Seibert, G., Maidhof, A., Müller, W.E. Antimicrob. Agents Chemother. (1984) [Pubmed]
  10. Comparison of cefodizime with various cephalosporins for their indirect effect on the human neutrophil oxidative burst in vitro. Labro, M.T., el Benna, J. J. Antimicrob. Chemother. (1990) [Pubmed]
  11. Electrophoretic mobility of cefodizime-treated Staphylococcus aureus and chemiluminescence of human polymorphonuclear leucocytes. Muratsugu, M., Tomonaga, M., Miyake, Y., Terayama, K., Ishida, N. J. Antimicrob. Chemother. (1991) [Pubmed]
  12. Reduced anti-Pseudomonas aeruginosa activity of a cephalosporin, cefodizime, in rats whose neutrophils were selectively depleted by a monoclonal antibody. Araki, A., Sendo, F. Microbiol. Immunol. (1996) [Pubmed]
  13. In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin. Jones, R.N., Barry, A.L., Thornsberry, C., Wilson, H.W. Antimicrob. Agents Chemother. (1981) [Pubmed]
  14. In vitro activity and beta-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin. Scully, B.E., Jules, K., Neu, H.C. Antimicrob. Agents Chemother. (1983) [Pubmed]
  15. Influence of cefodizime on chemotaxis and the respiratory burst in neutrophils from diabetics. Shaio, M.F., Chang, F.Y. J. Antimicrob. Chemother. (1990) [Pubmed]
  16. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Barradell, L.B., Brogden, R.N. Drugs (1992) [Pubmed]
  17. Cefodizime as a biological response modifier: a review of its in-vivo, ex-vivo and in-vitro immunomodulatory properties. Labro, M.T. J. Antimicrob. Chemother. (1990) [Pubmed]
  18. Effects of cefotaxime and cefodizime on human granulocyte functions in vitro. Labro, M.T., Babin-Chevaye, C., Hakim, J. J. Antimicrob. Chemother. (1986) [Pubmed]
  19. Pharmacokinetics of cefodizime: a review of the data on file. Barré, J. J. Antimicrob. Chemother. (1990) [Pubmed]
  20. Cefodizime (HR 221) potentiation of human neutrophil oxygen-independent bactericidal activity. Labro, M.T., Amit, N., Babin-Chevaye, C., Hakim, J. J. Antimicrob. Chemother. (1987) [Pubmed]
  21. Cefodizime modulates in vitro tumor necrosis factor-alpha, interleukin-6 and interleukin-8 release from human peripheral monocytes. Meloni, F., Ballabio, P., Bianchi, L., Grassi, F.A., Gialdroni Grassi, G.G. Chemotherapy. (1995) [Pubmed]
  22. Antibiotics and production of granulocyte-macrophage colony-stimulating factor by human bronchial epithelial cells in vitro. A comparison of cefodizime and ceftriaxone. Pacheco, Y., Hosni, R., Dagrosa, E.E., Gormand, F., Guibert, B., Chabannes, B., Lagarde, M., Perrin-Fayolle, M. Arzneimittel-Forschung. (1994) [Pubmed]
  23. Changes in lymphocyte subpopulations in patients treated with cefodizime for acute lower respiratory tract infections. Valcke, Y., Van der Straeten, M. Infection (1992) [Pubmed]
  24. The feedsideward of cephalo-adrenal immune interactions. Sánchez de la Peña, S. Chronobiologia. (1993) [Pubmed]
  25. An open multicentre study of the efficacy and tolerance of cefodizime 1 g bd intravenously or intramuscularly in lower respiratory tract infections. Sollet, J.P. J. Antimicrob. Chemother. (1990) [Pubmed]
  26. Pharmacokinetics of cefodizime during continuous ambulatory peritoneal dialysis. Mendes, P., Lameire, N., Rosenkranz, B., Malerczyk, V., Damm, D. J. Antimicrob. Chemother. (1990) [Pubmed]
 
WikiGenes - Universities